Evidence map›Paper›PMID 40348909›Full record

ReviewArchives of microbiology2025

Pseudomonas aeruginosa biofilm: treatment strategies to combat infection.

Rashmi Ramesh, N D Rekha, Shubha Gopal

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Genetic Determinants Linked to MDR/XDR inPathogens (Basel, Switzerland) · 2026
    Article
  2. Mapping the knowledge landscape ofFrontiers in cellular and infection microbiology · 2026
    Review
  3. Article
  4. Sub-inhibitory tobramycin concentration suppresses ToxA and LipA in single- and dual-species biofilms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rashmi RameshDepartment of Studies in Microbiology, University of Mysore, Manasagangotri, Mysuru, Karnataka, India.ORCID http://orcid.org/0000-0002-6769-3708
N D RekhaDepartment of Biotechnology, JSS College of Arts, Commerce and Science (Autonomous), Mysuru, Karnataka, India.
Shubha GopalDepartment of Studies in Microbiology, University of Mysore, Manasagangotri, Mysuru, Karnataka, India. sguom@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pseudomonas aeruginosa is an opportunistic human pathogenic bacterium that is a common cause of both acute and chronic infections. Multidrug-resistant P. aeruginosa poses a significant challenge to antibiotics and therapeutic approaches due to its pathogenicity, virulence, and biofilm-forming ability mediated by quorum sensing. Understanding the pathogenic mechanisms is essential for developing potential drug targets. In this regard, strategies aimed at combating the targeted inhibition of virulence, quorum sensing pathways, secretion systems, biofilm-associated two-component systems, and signalling system regulators (such as c-di-GMP) associated with biofilm formation are critical. Several new antimicrobial agents have been developed using these strategies, including antimicrobial peptides, bacteriophages, nanoantibiotics, photodynamics, and natural products, which are considered promising therapeutic tools. In this review, we address the concept of biofilms, their regulation, and recent treatment strategies to target P. aeruginosa, a clinically significant pathogen known for biofilm formation.

Indexed as

Anti-Bacterial AgentsBiofilmsPseudomonas aeruginosaPseudomonas InfectionsHumansQuorum SensingVirulenceAnti-Bacterial AgentsBiofilmPseudomonas aeruginosaQuorum sensingTherapeutic targets

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.